Dateline City: KENILWORTH, N.J. Only PARP Inhibitor to Improve Overall Survival vs. Enzalutamide or Abiraterone…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. Gefapixant (45 mg Twice Daily) Demonstrated Statistically Significant Decrease in 24-hour…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J. — Merck (NYSE: MRK), known as MSD outside the…
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United…
Dateline City: KENILWORTH, N.J. KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Certain Patients With…
Dateline City: KENILWORTH, N.J. KEYTRUDA Now Approved for Six Cancer Types Plus Microsatellite Instability-High (MSI-H)…
Dateline City: KENILWORTH, N.J. Third Approval for KEYTRUDA in First-Line NSCLC in China in Less…
Dateline City: KENILWORTH, N.J. KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the…